Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more
Medeon Biodesign (6499) - Net Assets
Latest net assets as of June 2025: NT$1.13 Billion TWD
Based on the latest financial reports, Medeon Biodesign (6499) has net assets worth NT$1.13 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.42 Billion) and total liabilities (NT$284.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.13 Billion |
| % of Total Assets | 79.92% |
| Annual Growth Rate | 0.03% |
| 5-Year Change | -41.99% |
| 10-Year Change | N/A |
| Growth Volatility | 31.83 |
Medeon Biodesign - Net Assets Trend (2017–2024)
This chart illustrates how Medeon Biodesign's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medeon Biodesign (2017–2024)
The table below shows the annual net assets of Medeon Biodesign from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.54 Billion | -35.23% |
| 2023-12-31 | NT$2.37 Billion | -35.27% |
| 2022-12-31 | NT$3.66 Billion | -12.53% |
| 2021-12-31 | NT$4.19 Billion | +58.20% |
| 2020-12-31 | NT$2.65 Billion | +17.73% |
| 2019-12-31 | NT$2.25 Billion | +25.03% |
| 2018-12-31 | NT$1.80 Billion | +17.33% |
| 2017-12-31 | NT$1.53 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medeon Biodesign's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 54156500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$2.53 Billion | 166.61% |
| Total Equity | NT$1.52 Billion | 100.00% |
Medeon Biodesign Competitors by Market Cap
The table below lists competitors of Medeon Biodesign ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Stoneridge Inc
NYSE:SRI
|
$139.55 Million |
|
TVS Srichakra Limited
NSE:TVSSRICHAK
|
$139.59 Million |
|
Fireweed Zinc Ltd
OTCQX:FWEDF
|
$139.60 Million |
|
ELEDON PHARMACEUT.DL-001
F:2TK
|
$139.71 Million |
|
Sindoh
KO:029530
|
$139.55 Million |
|
WildBrain Ltd
PINK:WLDBF
|
$139.54 Million |
|
EPC Groupe
PA:EXPL
|
$139.39 Million |
|
Willow Lane Acquisition Corp. Unit
NASDAQ:WLACU
|
$139.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medeon Biodesign's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,319,988,000 to 1,520,192,000, a change of -799,796,000 (-34.5%).
- Net loss of 805,512,000 reduced equity.
- New share issuances of 3,847,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-805.51 Million | -52.99% |
| Share Issuances | NT$3.85 Million | +0.25% |
| Other Changes | NT$1.87 Million | +0.12% |
| Total Change | NT$- | -34.47% |
Book Value vs Market Value Analysis
This analysis compares Medeon Biodesign's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.34x to 5.61x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$21.33 | NT$92.50 | x |
| 2018-12-31 | NT$25.99 | NT$92.50 | x |
| 2019-12-31 | NT$27.40 | NT$92.50 | x |
| 2020-12-31 | NT$28.12 | NT$92.50 | x |
| 2021-12-31 | NT$56.64 | NT$92.50 | x |
| 2022-12-31 | NT$41.05 | NT$92.50 | x |
| 2023-12-31 | NT$25.21 | NT$92.50 | x |
| 2024-12-31 | NT$16.50 | NT$92.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medeon Biodesign utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -52.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -275.10%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.24x
- Recent ROE (-52.99%) is below the historical average (-11.49%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -18.43% | -150.22% | 0.10x | 1.22x | NT$-381.84 Million |
| 2018 | 15.65% | 38.10% | 0.35x | 1.19x | NT$92.68 Million |
| 2019 | -13.07% | -57.74% | 0.18x | 1.26x | NT$-462.41 Million |
| 2020 | -9.42% | -29.47% | 0.20x | 1.62x | NT$-397.24 Million |
| 2021 | 50.32% | 3013.75% | 0.02x | 1.06x | NT$1.67 Billion |
| 2022 | -12.06% | -145.40% | 0.07x | 1.12x | NT$-793.50 Million |
| 2023 | -51.92% | -613.78% | 0.07x | 1.18x | NT$-1.44 Billion |
| 2024 | -52.99% | -275.10% | 0.16x | 1.24x | NT$-957.53 Million |
Industry Comparison
This section compares Medeon Biodesign's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,796,147,300
- Average return on equity (ROE) among peers: 10.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medeon Biodesign (6499) | NT$1.13 Billion | -18.43% | 0.25x | $139.55 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Nang Kuang Pharmaceutical Co Ltd (1752) | $2.19 Billion | 9.94% | 0.50x | $46.91 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |